Bioactive peptides control receptor for advanced glycated end product-induced elevation of kidney insulin receptor substrate 2 and reduce albuminuria in diabetic mice

American Journal of Nephrology

Volumn 28, Issue 6, 2008, Pages 890-899

  Singh, Baljit K ^a,b   Mascarenhas, Desmond D ^a,b  

^a Mayflower Organization for Research and Education   (United States)

^b Protigen Inc   (United States)

Author keywords

Albuminuria; Diabetes; Humanin; Insulin receptor substrate 2; Nephropathy; Receptor for advanced glycated end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOCHEMICAL MARKER; COLLAGEN TYPE 4; GLUCOSE; HUMANIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MUTANT PROTEIN; PROTEIN KINASE B; PROTEIN KINASE C; SERINE; THREONINE; TISSUE EXTRACT;

ALBUMINURIA; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; KIDNEY; KIDNEY CELL; KIDNEY DYSFUNCTION; KIDNEY PARENCHYMA; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; WILD TYPE;

ALBUMINURIA; ANIMALS; COLLAGEN TYPE IV; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBINS; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; KIDNEY; MICE; MODELS, BIOLOGICAL; PEPTIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 53549103549     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000141042     Document Type: Article

References (26)

1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
2. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393.
3. Goldin A, Beckman JA, Schmidt AM, Creager MA: Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597-605.
4. Tan AL, Forbes JM, Cooper ME: AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 2007;27:130-143.
5. Yamagishi S, Matsui T, Nakamura K: Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007;8:1138-1143.
6. Koyama H, Yamamoto H, Nishizawa Y: RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 2007;13:625-635.
7. Tsilibary EC: Microvascular basement membranes in diabetes mellitus. J Pathol 2003;200:537-546.
8. Tuttle KR, Anderson PW: A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis 2003;42:456-465.
9. Ron D, Luo J, Mochly-Rosen D: C2 region-derived peptides inhibit translocation and function of beta protein kinase C in vivo. J Biol Chem 1995;270:24180-24187.
10. Peterson LE: Partitioning large-sample microarray-based gene expression profiles using principal components analysis. Comput Methods Programs Biomed 2003;70:107-119.
11. Niikura T, Hashimoto Y, Tajima H, Nishimoto I: Death and survival of neuronal cells exposed to Alzheimer's insults. J Neurosci Res 2002;70:380-391.
12. Chiba T, Nishimoto I, Aiso S, Matsuoka M: Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide colivelin. Mol Neurobiol 2007;35:55-84.
13. Singh B, Charkowicz D, Mascarenhas D: Insulin-like growth factor-independent effects mediated by a C-terminal metal-binding domain of insulin-like growth factor binding protein-3. J Biol Chem 2004;279:477-487.
14. Agutter PS: Cell mechanics and stress: from molecular details to the 'universal cell reaction' and hormesis. Bioessays 2007;29:324-333.
15. Kültz D: Molecular and evolutionary basis of the cellular stress response. Annu Rev Physiol 2005;67:225-257.
16. Bjedov I, Tenaillon O, Gérard B, Souza V, Denamur E, Radman M, Taddei F, Matic I: Stress-induced mutagenesis in bacteria. Science 2003;300:1404-1409.
17. Matic I, Taddei F, Radman M: Survival versus maintenance of genetic stability: a conflict of priorities during stress. Res Microbiol 2004;155:337-341.
18. Giovannone B, Scaldaferri ML, Federici M, Porzio O, Lauro D, Fusco A, Sbraccia P, Borboni P, Lauro R, Sesti G: Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab Res Rev 2000;16:434-441.
19. White MF: Regulating insulin signaling and beta-cell function through IRS proteins. Can J Physiol Pharmacol 2006;84:725-737.
20. Gibson SL, Ma Z, Shaw LM: Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 2007;6:631-637.
21. Draznin B: Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes 2006;55:2392-2397.
22. Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-1274.
23. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/ PKB by the rictor-mTOR complex. Science 2005;307:1098-1101.
24. Freeley M, Park J, Yang KJ, Wange RL, Volkov Y, Kelleher D, Long A: Loss of PTEN expression does not contribute to PDK-1 activity and PKC activation-loop phosphorylation in Jurkat leukaemic T cells. Cell Signal 2007;19:2444-2457.
25. Kawakami Y, Nishimoto H, Kitaura J, Maeda-Yamamoto M, Kato RM, Littman DR, Leitges M, Rawlings DJ, Kawakami T: Protein kinase C beta II regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem 2004;279:47720-47725.
26. Tajima H, Kawasumi M, Chiba T, Yamada M, Yamashita K, Nawa M, Kita Y, Kouyama K, Aiso S, Matsuoka M, Niikura T, Nishimoto I: A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice. J Neurosci Res 2005;79:714-723.